Srinivasulu Cheemanapalli1, Madhusudana Pulaganti1, Srinivasulus B1, Nagaraju C1, Anuradha CM2, Chitta Suresh Kumar1*
1BIF, Department of Biochemistry, Sri Krishnadevaraya University, Anantapuramu-515003, A.P, India
2Departmentof Biotechnology, Sri Krishnadevaraya University, Anantapuramu-515003, A.P, India.
APOTHEKE-2014, 8 Nov 2014, Organized by Balaji College of Pharmacy, Ananthapuramu, Andhra Pradesh, India
Polo like kinases (Plks) play a multiful role in the cell cycle progression and its mis-regulation in cancer believed as a promising anticancer-drug target. The N-terminal polo box domain(PBD) of plk1is another efficient target for potent plk1 inhibition. Natural Aristolactam analogues have shown anticancer activity,but their cellular target was unknown. In this work, molecular docking studies were performed in order to see the interaction of Aristolactam and its 11analogues with human plk1 in cancer. Results shown that among 11, three analogues exhibited good affinity to the PBD of plk1 with free energy of -8.10,-7.47 and -7.10 Kcal/mol and inhibition constant(Ki) of 1.16,3.33 and 6.61 µM. Active site residues of PBD interacting with Aristolactam analogues were Trp414, Lys540, Leu491, Asn533, Ser412, Arg516, Arg594, Asp371 and Tyr510. The inhibitor for the plk1,BI2523 was used as reference drug and it was shown poor docking energy compared to Aristolactam analogues. In binding mode, the length (Å) of H-bonds were varied from each analogue. These interactions indicated that stability of Aristolactams in PBD of plk1 and suggested as a potential drug candidates. Thus good affinity of Aristolactam analogues to plk1 may leads to synthesis of anticancer drugs.
Keywords: Cancer, Aristolactams, Polo like kinse-1, molecular docking and polo box domain.